Trial Profile
A Phase III, Randomized, Double-Blind. Placebo-Controlled, Multi-Center Study of Systemic Lupus Erythematosus With Acute Severe SLE Flares Excluding Renal or Neurological Systems.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Epratuzumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Registrational; Therapeutic Use
- Acronyms ALLEVIATE-1
- Sponsors Immunomedics; UCB; UCB Pharma Inc
- 13 Jun 2012 New trial record
- 08 Jun 2012 Results presented at the 13th Annual Congress of the European League Against Rheumatism, according to an Immunomedics media release.